skip to Main Content
  • This page as PDF
April 30, 2020 9:00 - 10:00 PM ET

Understanding Shifts from Medicare Part B to D in Autoimmune Treatment


Avalere experts will examine evolving stakeholder-specific considerations for reshaping how patients with autoimmune conditions receive care during and after the COVID-19 pandemic.

Treatment for autoimmune conditions continue to see significant Medicare program changes during the COVID-19 pandemic. Current shifts and flexibilities attempt to mitigate the interruptions in care through providing solutions that balance safety and access to necessary treatment. However, these health system disruptions resulting from COVID-19 are significantly reshaping how patients receive care. Unanticipated changes in utilization, such as a large shift from provider-administered to self-administered drugs, will impact coverage, utilization management, and health plan costs. Additionally, there are clinical challenges that must be closely considered by patients and physicians for transition to a new therapy. All healthcare stakeholders will need to understand the immediate and future effects of these changes.

Key topics will include:

  • Policy shifts during COVID-19
  • Current status of Medicare Part B and D
  • Provider and patient access and impact
  • Future state of the Medicare B and D benefits
  • Coverage and cost implications


Sarah Butler , Head, Client Solutions, Marketing & Operations, Client Solutions

Sarah Butler is the head of Sales, Marketing, and Operations.

Kayla Amodeo , Associate Principal, Policy

Kayla Amodeo serves as a key subject-matter expert on Medicare Part B, drug pricing, and value assessment policy-related issues impacting the pharmaceutical industry, physicians, the federal government, and other stakeholders.

John E. Linnehan , Practice Director, Health Economics & Advanced Analytics

John E. Linnehan leads our Health Economics and Advanced Analytics Practice, a team of consultants, strategists, and data scientists focused on driving healthcare improvement through value demonstration, stakeholder engagement, predictive and applied analytics, and data innovations.

Michael Schneider , Principal, Commercialization & Regulatory Strategy
From beginning to end, our team synergy
produces measurable results. Let's work together.
Back To Top